Abstract
Colorectal cancer is a common malignant tumor in the world. Oxaliplatin is the third-generation platinum drug and commonly used in colorectal cancer, its chemotherapy-based regimen has become the standard for chemotherapy for colorectal cancer. An important reason of colorectal cancer chemotherapy failure is the development of drug resistance of tumor cells to chemotherapy drugs. Recent studies have found that the combination of targeting modifiers and chemotherapeutic drugs can increase the local concentration of chemotherapeutic drugs in the tumor tissue. iRGD peptide, as a mediator in combination with chemotherapeutic drugs, potentiates the chemotherapeutic effect, intravascular injection of a chemotherapeutic drug modified with the iRGD peptide can cause the chemotherapeutic drug to bind to the tumor blood vessel and spread to the extravascular tumor mass. In this paper, advances in research of iRGD peptide cooperating with oxaliplatin in reversing colorectal cancer drug resistance are reviewed in detail. Key words: Colorectal neoplasms; Drug Resistance, Neoplasm; iRGD peptide; Oxaliplatin; Research progress
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call